Healthcare Providers and Services
Company Overview of Enzo Clinical Labs, Inc.
Enzo Clinical Labs, Inc. operates clinical reference laboratories in the United States. It offers various assays in the areas of chemistry, fertility and hormone studies, pregnancy, hematology, and coagulation. The company also provides electronic report delivery services for physicians. In addition, it offers phlebotomy services for patients needing blood tests through its network of patient service centers; diagnostic test that assists in risk assessment and early detection of lung cancer; and ColonSentry, a blood test to assess an individual's current risk for colorectal cancer. Enzo Clinical Labs, Inc. is based in Farmingdale, New York. The company has patient service centers in Manhatta...
60 Executive Boulevard
Farmingdale, NY 11735
Key Executives for Enzo Clinical Labs, Inc.
Chairman of the Board and Chief Executive Officer
President of Enzo Biochem Inc
Vice President of Corporate Development
Scientific Director and Associate Medical Director
Compensation as of Fiscal Year 2014.
Enzo Clinical Labs, Inc. Key Developments
Enzo Clinical Labs and Nuclea Biotechnologies Join to Market New Test for Certain High Risk Breast Cancer Patients
Feb 18 14
Enzo Biochem Inc. announced that its Enzo Clinical Labs subsidiary and Nuclea Biotechnologies, Inc. have entered into a non-exclusive distribution agreement to market Nuclea's non-invasive HER-2/neu serum test, a key assay in the monitoring of metastatic breast cancer. This blood test facilitates the monitoring and treatment decisions of women with metastatic breast cancer that over expresses the HER-2/neu protein in the tumor. Individuals with this condition tend to have a worse prognosis and a more aggressive disease that can resist certain types of chemotherapy. The test measures the portion of HER-2/neu protein that lies outside the surface of the cell and being released into the blood stream, allowing for more informed treatment decisions for a number of women who may not be responding to breast cancer treatment or may be at risk for metastatic cancer and need revised treatment plans. Utilizing the HER-2/neu blood test while monitoring the disease's progression will enable physicians to better adapt, combine therapies and change treatment protocols. Studies have demonstrated that use of combination chemotherapy regimens provides a statistically significant advantage for survival and tumor response in women with metastatic breast cancer.
The Enzo Clinical Labs. and Sequenom Laboratories, Inc. Partner to Market Key Sequenom Laboratories Prenatal Testing Service
Oct 29 13
The Enzo Clinical Labs entered into an agreement to market in its northeast U.S. service area a proprietary early non-invasive prenatal laboratory test service, MaterniT21 PLUS (TM), developed by the Sequenom Laboratories, Inc.
Enzo Biochem's Enzo Clinical Labs, Inc. Introduces Diagnostic Test That Assists in Early Detection of Lung Cancer
Nov 13 12
Enzo Biochem Inc. announced that its Enzo Clinical Labs, Inc. has introduced a new diagnostic test that assists in risk assessment and early detection of lung cancer. It is being made available to physicians in the New York metropolitan market as well as New Jersey and Eastern Pennsylvania, where Enzo is the only clinical laboratory making the test available within those areas. EarlyCDT-Lung has been approved by the New York State Department of Health. Utilizing a simple blood specimen, the test is directed at patients with a high risk of developing lung cancer, including heavy smokers, those exposed to suspect environmental conditions, and patients with a CT nodule under surveillance. The availability of EarlyCDT-Lung by Enzo Clinical Labs is the result of an agreement with its developer, Kansas-based Oncimmune(R). The agreement provides for Enzo to be the only clinical laboratory located within its marketing area to make the test available to physicians. EarlyCDT-Lung uses a panel of tumor antigens that are selected for their involvement in the development of lung cancer. Autoantibodies form and circulate in the body at all stages of the disease including Stages I and IIA, which are the earliest stages of lung cancer. Their measurement may signify the presence of cancerous cells. The Oncimmune immuno-biomarker platform (EarlyCDT-Lung) provides increased sensitivity while maintaining higher levels of specificity than other single or multiple antigen tests. Elevation above a predetermined cutoff value of any one immuno-biomarker of the panel suggests that a tumor might be present. While risk assessment and early detection of lung cancer in asymptomatic high-risk patient populations are the primary benefits of EarlyCDT-Lung, it is also valuable as a follow-up test for high-risk patients who have indeterminate lung nodules identified by CT.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|